Investigation Report on China Rivaroxaban Market, 2010-2019
Description
Venous Thrombus Embolism (VTE), the general term for deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a grave threat to those patients who have accepted Total Hip Replacement (THR) or Total Knee Replacement (TKR). It is estimated that blood clots form in 50% of THR patients and 60% of TKR patients.
According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Bayer/ Johnson & Johnson. In Oct. 2008, rivaroxaban was approved to come into the Canada and the EU markete under the trade name of Xarelto while on Jul. 1, 2011, it was approved by FDA to enter the American market. Rivaroxaban has been approved by more than 100 countries in the world and succeeded in entering over 75 countries. According to the statistics of Bayer/ Johnson & Johnson, the sales value of rivaroxaban in the world exceeded USD 2.124 billion in 2013, increasing by 219% compared with last year.
After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter half of 2009, it develops fast with annual sales rising from less than CNY 20 million in 2010 to CNY 140 million in 2014 and CAGR reaching up to over 70% during the period of 2010-2014. Currently, the rivaroxaban market in China has been monopolized by Bayer. The price of rivaroxaban is relatively high for it is imported. The price range of 10 mg rivaroxaban (tablets, 5 tab. per package) is 364.20-388.68 CNY/package in sample hospitals with cities differing slightly in its price. Some Chinese enterprises have been developing the generic drugs of rivaroxaban. And it is estimated that the market size of rivaroxaban in China will keep expanding in the next few years.
Readers can get at least the following information through this report:
Venous Thrombus Embolism (VTE), the general term for deep vein thrombosis (DVT) and pulmonary embolism (PE), poses a grave threat to those patients who have accepted Total Hip Replacement (THR) or Total Knee Replacement (TKR). It is estimated that blood clots form in 50% of THR patients and 60% of TKR patients.
According to some experts, rivaroxaban and dabigatran are the most promising antithrombotic agents which will add a new milestone to the development of cardiovascular drugs. Rivaroxaban is the first available orally active direct factor Xa inhibitor developed by Bayer/ Johnson & Johnson. In Oct. 2008, rivaroxaban was approved to come into the Canada and the EU markete under the trade name of Xarelto while on Jul. 1, 2011, it was approved by FDA to enter the American market. Rivaroxaban has been approved by more than 100 countries in the world and succeeded in entering over 75 countries. According to the statistics of Bayer/ Johnson & Johnson, the sales value of rivaroxaban in the world exceeded USD 2.124 billion in 2013, increasing by 219% compared with last year.
After rivaroxaban entering the Chinese market under the trade name of Xarelto in the latter half of 2009, it develops fast with annual sales rising from less than CNY 20 million in 2010 to CNY 140 million in 2014 and CAGR reaching up to over 70% during the period of 2010-2014. Currently, the rivaroxaban market in China has been monopolized by Bayer. The price of rivaroxaban is relatively high for it is imported. The price range of 10 mg rivaroxaban (tablets, 5 tab. per package) is 364.20-388.68 CNY/package in sample hospitals with cities differing slightly in its price. Some Chinese enterprises have been developing the generic drugs of rivaroxaban. And it is estimated that the market size of rivaroxaban in China will keep expanding in the next few years.
Readers can get at least the following information through this report:
- market share of manufacturers of rivaroxaban in Chinese hospitals
- price of rivaroxaban in Chinese hospitals
- major manufacturers of rivaroxaban
- share of different dosage forms of rivaroxaban in Chinese hospitals
- market outlook of rivaroxaban in China
- manufacturers of antithrombotic agents
- investors/ research institutions interested in Chinese medicine market
- any interest in Chinese medicine market, please contact CRI for customized survey service
1 RELATED CONCEPTS OF RIVAROXABAN
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF RIVAROXABAN IN CHINA
2.1 Patent and Approval Status of Rivaroxaban in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF RIVAROXABAN IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF RIVAROXABAN IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF RIVAROXABAN IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF RIVAROXABAN IN CHINESE HOSPITALS IN 2014
7 MAJOR MANUFACTURERS OF RIVAROXABAN IN CHINESE MARKET, 2010-2014
7.1 Bayer HealthCare
7.2 Bayer AG (Germany)
8 MARKET OUTLOOK OF RIVAROXABAN IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landsacpe
1.1 Indication
1.2 Sales Status in Global Market
2 MARKET PROFILE OF RIVAROXABAN IN CHINA
2.1 Patent and Approval Status of Rivaroxaban in China
2.2 Major Manufacturers
2.3 Market Size
3 SURVEY ON SALES STATUS OF RIVAROXABAN IN CHINA, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions
4 SURVEY ON MARKET SHARE OF MAJOR MANUFACTURERS OF RIVAROXABAN IN CHINA, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume
5 SURVEY ON DOSAGE FORMS OF RIVAROXABAN IN CHINA, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume
6 REFERENCE PRICE OF RIVAROXABAN IN CHINESE HOSPITALS IN 2014
7 MAJOR MANUFACTURERS OF RIVAROXABAN IN CHINESE MARKET, 2010-2014
7.1 Bayer HealthCare
7.2 Bayer AG (Germany)
8 MARKET OUTLOOK OF RIVAROXABAN IN CHINA, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landsacpe
SELECTED CHARTS
Chart Patent Status of Rivaroxaban in China
Chart Approval Information of Rivaroxaban in China
Chart Sales Status of Rivaroxaban in Chinese Market, 2010-2014
Chart Sales Value of Rivaroxaban in China, 2010-2014
Chart Sales Value of Rivaroxaban in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Rivaroxaban Made by Bayer (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Rivaroxaban Made by Beijign Bayer in China, 2010-2014
Chart Price of Rivaroxaban Made by Bayer (Germany) in Some Chinese Cities in 2014
Chart Patent Status of Rivaroxaban in China
Chart Approval Information of Rivaroxaban in China
Chart Sales Status of Rivaroxaban in Chinese Market, 2010-2014
Chart Sales Value of Rivaroxaban in China, 2010-2014
Chart Sales Value of Rivaroxaban in Some Regions in China, 2010-2014
Chart Sales Value and Market Share of Rivaroxaban Made by Bayer (Germany) in China, 2010-2014
Chart Sales Value and Market Share of Rivaroxaban Made by Beijign Bayer in China, 2010-2014
Chart Price of Rivaroxaban Made by Bayer (Germany) in Some Chinese Cities in 2014
